EXELPhase 3 Readout

STELLAR pivotal study top-line data

Exelixis | Zanzalintinib | Renal cell carcinoma

Catalyst details

Late-stage oncology catalyst monitored with SEC and press release updates.

Phase

Phase 3

Expected date

2026-09-30

Expected period

2H 2026

Source type

manual

half yearupcoming
Source URL

Notes

This record is structured for public-source tracking and manual analyst override. The database stores date confidence separately from exact dates so quarter, half-year, and estimated guidance can be handled without inventing precision.

Open company detail

History of changes

No sample changes for this catalyst.